ArticleCureus2025
Pseudoprogression of Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemoimmunotherapy is increasingly used in early-stage non-small cell lung cancer (NSCLC) and has demonstrated improved pathological response rates. However, radiological progression following treatment may result in potentially curative surgery being withheld. We report the case of a 75-year-old male with a poorly differentiated adenocarcinoma of the right lower lobe lung adenocarcinoma treated with neoadjuvant carboplatin, paclitaxel, and nivolumab. Post-treatment CT scan showed radiological progression. The patient underwent video-assisted thoracoscopic right lower lobectomy with posterior segmentectomy. Histopathological examination revealed a complete pathological response with no viable tumor and no nodal involvement. This case highlights the importance of recognizing pseudoprogression in the neoadjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.